Eli Lilly & Co. Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Eli Lilly and Company's (LLY) Form 10-Q for the quarterly period ended June 30, 2024. The company operates as a single segment focused on the discovery, development, manufacturing, and marketing of pharmaceutical products globally. The reporting period reflects significant growth driven by the commercialization of incretin medicines (Mounjaro and Zepbound) and oncology products (Verzenio), alongside continued investment in manufacturing capacity and R&D.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $11,302.8M | $8,312.1M | $20,070.8M | $15,272.1M |
| Net Income | $2,967.0M | $1,763.2M | $5,209.9M | $3,108.1M |
| Diluted EPS | $3.28 | $1.95 | $5.76 | $3.44 |
| Gross Margin % | 80.8% | 78.3% | 80.8% | 77.5% |
| Operating Cash Flow (YTD) | $2,632.2M | $2,362.5M | - | - |
| Total Debt | $28.89B | - | - | - |
| Cash & Equivalents | $3.22B | - | - | - |
Note: Debt and Cash figures represent balances as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 36% in Q2 and 31% YTD compared to the prior year. Growth was driven by volume increases (27% in Q2) and higher realized prices (10% in Q2), primarily from Mounjaro, Zepbound, and Verzenio.
- Product Performance:
- Mounjaro: Q2 revenue reached $3.09B (up from $979.7M in Q2 2023).
- Zepbound: Q2 revenue was $1.24B (new product launched late 2023).
- Trulicity: Revenue declined 31% in Q2 due to supply constraints and competitive dynamics.
- Verzenio: Revenue increased 44% in Q2.
- Expenses: R&D expenses rose 15% in Q2 to $2.71B. A one-time charge of $435.0M was recorded for asset impairment, restructuring, and other special charges related to anticipated litigation payments.
- Debt Issuance: In February 2024, the company issued $6.50B in fixed-rate notes to fund general business purposes and repay commercial paper.
Outlook, Risks, and Management Commentary
- Supply Chain: Demand for incretin medicines continues to exceed production. While supply and demand are balancing, the company expects periodic tightness. Sales growth for these products remains a function of production capacity. The company is expanding manufacturing and exploring new delivery presentations (e.g., single-use vials).
- Acquisitions: In July 2024, Lilly announced an agreement to acquire Morphic Holding, Inc. for approximately $3.2B. The company also acquired a manufacturing facility in Wisconsin for $924.7M in May 2024.
- Regulatory & Pricing Risks: The Inflation Reduction Act (IRA) poses pricing risks; Jardiance was selected for government price setting effective in 2026. The company faces ongoing litigation regarding insulin pricing, the 340B program, and product liability (e.g., Mounjaro/Trulicity lawsuits).
- Dividends: Cash dividends declared were $2.60 per share for the quarter.
Key Facts for Investor Verification
- Supply Constraints: Verify the timeline for new manufacturing capacity coming online to meet demand for Mounjaro and Zepbound, as this is the primary limiter on revenue growth.
- One-Time Charges: Confirm the specific nature and potential future exposure of the $435M litigation-related charge recorded in Q2.
- IRA Impact: Monitor the selection of additional products for price negotiation under the Inflation Reduction Act beyond Jardiance.
- Acquisition Integration: Track the closing conditions and integration progress of the $3.2B Morphic acquisition announced in July 2024.
- Trulicity Decline: Assess the long-term trajectory of Trulicity revenue as it faces competition from newer GLP-1/GIP agonists and supply management strategies.